Grow Talk
A place to hang out, talk grow, and help each other become better growers.
Organizer:
- Organized by
-
-
The Daily Dose
-
The Daily Dose
The Daily Dose 01/08/2025
DEA Judge Orders Agency To Respond To New Allegations It Opposes Marijuana Rescheduling And Improperly Conspired With Prohibitionists
Published on
January 8, 2025
By
Kyle JaegerA Drug Enforcement Administration (DEA) judge has ordered the agency to respond to new allegations that it opposes the Biden administration’s marijuana rescheduling proposal it is supposed to be defending and that it had additional improper communications with opponents of the reform.
Just one day after a motion outlining the allegations was filed by several witnesses set to participate in hearings that begin later this month, DEA Administrative Law Judge (ALJ) John Mulrooney issued a briefing order on Tuesday mandating that the agency reply by next week.
Village Farms International, Hemp for Victory, the Connecticut Office of the Cannabis Ombudsman, Ellen Brown and My Doc App are ultimately asking the judge to remove DEA as the proponent of the proposed rule to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). “The Motion for Reconsideration requests a series of relief related to alleged improper ex parte communications between the Agency and other actors,” Mulrooney said. “The Government is herein ORDERED to file a response to the Motion to Reconsider” by January 13.
Part of the pro-rescheduling participants’ motion addresses a new declaration submitted to the ALJ by a DEA official last week, wherein the agency pharmacologist seemed to question the basis of the reclassification proposal by echoing “anti-rescheduling talking points in attempting to show that marijuana has a high abuse potential and no currently accepted medical use,” the cannabis groups said in their latest motion.
It says DEA based its analysis on a legal test that was previously rejected by the Justice Department’s Office of Legal Counsel (OLC), and the agency’s “defiance of OLC’s binding opinion is stunning proof of its open hostility to the Proposed Rule.”
Specifically, when assessing whether marijuana has currently accepted medical value, DEA used a five-factor review that OLC had described as “impermissibly narrow,” running counter to the two-factor review standard applied by the U.S. Department of Health and Human Services (HHS) to reach conclusion to recommend rescheduling.
What’s more, the attorneys said the timing of the DEA’s declaration filing is further evidence that DEA opposes the policy change, noting that the agency was statutorily required to submit any relevant data on the proposed rule before HHS carried out its scientific review and the rulemaking process was formally initiated.
The motion then alleges that there’s “additional damning evidence of ex parte and undisclosed communications has emerged,” with DEA failing to disclose nearly 100 requests to participate in the upcoming hearings, as well as “communication and coordination with at least one anti-rescheduling DP, the Tennessee Bureau of Investigation.”
One of the previously undisclosed requests to participate in the hearing came from the state of Colorado, which was denied by DEA despite the state’s extensive background in regulating cannabis. Yet the attorney general of Nebraska was permitted to serve as an anti-rescheduling witness.
“This new evidence confirms that DEA has worked to stack the deck against the Proposed Rule by favoring anti-rescheduling parties in its selection of hearing participants and obstructing a balanced and thoughtful process based on science and evidence,” the filing says.
The DEA judge rejected the cannabis groups’ earlier request to remove the agency as the proponent of the rescheduling rule, but he did seem to put weight into separate allegations that it engaged in unlawful communication with another DP, the prohibitionist group Smart Approaches to Marijuana (SAM).
Relatedly, a federal judge recently dismissed a lawsuit seeking to compel DEA to turn over its organization. Additionally, the latest motion asserts that recently published documents reveal that DEA lists another anti-drug group that’s participating in the hearing—Community Anti-Drug Coalitions of America (CADCA)—”as a resource for information on marijuana.”
Meanwhile, the DEA ALJ recently denied a cannabis research company’s request to allow it to add a young medical marijuana patient and advocate as a witness in the upcoming rescheduling hearing.
Mulrooney separately said last month that DEA made a critical “blunder” in its effort to issue subpoenas to force Food and Drug Administration (FDA) officials to testify in rescheduling process—but he allowed the agency to fix the error and ultimately granted the request. Also, one of the nation’s leading marijuana industry associations asked the judge to clarify whether it will be afforded the opportunity to cross-examine DEA during the upcoming hearings on the cannabis rescheduling proposal.
Further, a coalition of health professionals that advocates for cannabis reform recently asked that the DEA judge halt future marijuana rescheduling hearings until a federal court is able to address a series of allegations they’re raising about the agency’s witness selection process. That came on the same day the Mulrooney issued a ruling that laid out the timeline for merit-based hearings on the rescheduling proposal.
Doctors for Drug Policy Reform (D4DPR) requested that the DEA judge stay the hearings—which are currently set to commence on January 21—pending a review from the U.S. District Court for the District of Columbia Circuit. A separate organization that was also denied participation, Veterans Action Council (VAC), similarly filed a petition with the same court last month to request a review of the agency’s decision to exclude it from the proceedings.
In a prehearing statement submitted in November, DEA previewed the testimony its two agency witnesses plan to provide at the upcoming hearing—without clarifying where it stands on the rescheduling proposal. While the initial preliminary hearing happened last week, the merit-based proceedings were delayed until at least early 2025 after Mulrooney notified DEA that it provided insufficient information about the 25 selected witnesses that DEA Administrator Anne Milgram submitted.
Separately, the DEA judge has also denied a request from a cannabis and psychedelics researcher to postpone the upcoming rescheduling hearing over the agency’s alleged “improper blocking” of witnesses, while arguing that the process should be halted at least until President-elect Donald Trump’s administration comes into power so it can review the rulemaking.
Mulrooney also rejected a veterans group’s petition to participate in the rescheduling hearing, which the organization called a “travesty of justice” that excludes key voices that would be affected by the potential policy change. That group has asked the U.S. Court of Appeals for the D.C. Circuit to intervene on its behalf. For what it’s worth, Vice President Kamala Harris said recently that part of the reason for the delay in the administration’s marijuana rescheduling effort is federal bureaucracy that “slows things down,” including at DEA.
In March, Harris also expressed some frustration with the bureaucratic process of rescheduling marijuana, prior to DOJ’s formal recommendation, calling on DEA to expediently finish the job. While the Biden–Harris administration facilitated the review that led to the DOJ rescheduling proposal, Trump has also voiced support for the reform.
-
8 Replies
-
Somebody please bottom line it for me. I can’t read that
-
The DEA is allowing Anti-Cannabis Petitioners a voice but not the same voice for Pro-Cannabis Petitioners.
You’re getting shafted and they are trying to deny medical usage completely.
People hate on Edge as a browser but it will read pages to you. That makes it easier for me to read along and absorb the information on text only pages.
-
This reply was modified 20 hours, 35 minutes ago by ZoomyCat. Reason: You're not we're. Doesn't really apply to me but applies to friends
-
Oh dang, it’s microchip
No thanks
-
This reply was modified 20 hours, 35 minutes ago by
-
A DEA judge has ordered the agency to respond to allegations that it opposes marijuana rescheduling and engaged in improper communications with anti-reform groups. Critics accuse the DEA of bias in witness selection and using invalid legal standards to block reform. Hearings on rescheduling, set for January 21, face delays and legal challenges from excluded pro-rescheduling groups, while Vice President Harris has criticized bureaucratic slowdowns
-
-
Cool, nice tip. I’m checking it now
-
-
Sadly more BS to wade through 😑
-
-
The Daily Dose
1/9/2025
Cannabis Genetic ID Kits
Cannabis genetic identification kits have advanced significantly, offering growers precise tools to optimize cultivation. Here are some of the latest developments:
1. Early Plant Sex Identification:
GENE-UP® PRO GENDER ID by bioMérieux: This kit enables early identification of cannabis plant sex, compatible with both fresh and dried samples. It streamlines cultivation by allowing growers to determine plant sex early, enhancing operational efficiency and profitability.
FemINDICAtor® by Medicinal Genomics: Delivering 99% accurate results in less than 90 minutes, this qPCR-based assay allows growers to identify male plants just one week after germination, conserving resources and space.
StudFinder™ by Agdia: Targeting the Y chromosome DNA in cannabis, this molecular test can identify male plants as early as seven days post-germination, aiding in efficient crop management.
2. Genetic Trait Analysis:
Dynamic DNA Laboratories’ Cannabis DNA Test: This test helps users understand how their body metabolizes and reacts to cannabis by analyzing 13 genetic traits, guiding personalized dosing and product selection.
Genetic Cannabinoid Screening by Medicinal Genomics: These tools detect the presence of THCA and CBDA synthase genes in plants, assisting cultivators in predicting cannabinoid profiles and tailoring breeding programs accordingly.
3. Commercial Testing Services:
LeafWorks® Cannabis & Hemp DNA Sex Test: Offering 99% accuracy, this service identifies the gender of seedlings within seven days post-germination, enabling growers to remove unwanted male plants early and optimize yields.
Farmer Freeman’s EZ-XY Plant DNA Sex Test Kits: These kits allow growers to test plant sex early, maximizing crop potential by culling males before they impact yields or pollinate females.
————————————-
These advancements in cannabis genetic identification empower growers to make informed decisions, enhance crop quality, and improve overall efficiency in cultivation practices.
What are your thoughts on using genetic ID testing kits? Have you used any? Have you had success? Let’s hear your story DGC!
Log in to reply.
